Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00002162
- Locations
- 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸UCSD Treatment Ctr, San Diego, California, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT00002184
- Locations
- 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸UCLA Care Ctr, Los Angeles, California, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT00002367
- Locations
- 🇺🇸
AIDS Healthcare Foundation Labs, Los Angeles, California, United States
🇺🇸Urgent Care Ctr / North Broward Hosp District, Fort Lauderdale, Florida, United States
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Target Recruit Count
- 1250
- Registration Number
- NCT00002124
- Locations
- 🇺🇸
CARE Ctr / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Los Angeles County / Health Research Assoc / Drew Med Ctr, Los Angeles, California, United States
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2000
- Registration Number
- NCT00002368
- Locations
- 🇺🇸
Dr G Michael Wool, Los Angeles, California, United States
🇺🇸Northwestern Univ / Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸Rush Presbyterian / Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 100
- Registration Number
- NCT00005764
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
🇺🇸St Lukes Medical Group, San Diego, California, United States
3TC (Lamivudine; GR109714X) Open-Label Program
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002108
- Locations
- 🇺🇸
Kern - McNeill International, Morristown, New Jersey, United States
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00002241
- Locations
- 🇺🇸
Chelsea Village Med Ctr, New York, New York, United States
🇺🇸St Lukes / Roosevelt Hosp / HIV Center, New York, New York, United States
🇺🇸Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00002208
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Univ of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.